Global News Post Fastest Global News Portal
Related Articles
Flags with the trademarks of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss therapies Ozempic and Wegovy are photos whilst the corporate gifts the yearly file at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | Afp | Getty Images
Novo Nordisk on Wednesday reported a better-than-expected upward thrust in web benefit however diminished its full-year gross sales expansion forecast amid weaker gross sales of its blockbuster Wegovy weight reduction medicine.
The Danish pharmaceutical large’s web benefit got here in at 29.03 billion Danish kroner ($4.4 billion) for the three-month duration to the top of March, forward of the 27.8 billion Danish kroner forecast by means of analysts in an LSEG ballot.
Sales of the corporate’s standard Wegovy weight problems drug hit 17.36 billion Danish kroner over the duration, quite beneath the 18.51 billion Danish kroner expected by means of analysts in a Factset ballot Tuesday.
Overall revenues at Novo Nordisk — which additionally produces diabetes and uncommon illness therapies — got here in at 78.09 billion Danish kroner as opposed to an anticipated 78.18 million Danish kroner.
For 2025, the corporate now sees gross sales expansion of 13% to 21% at consistent change charges, beneath the 16% to 24% prior to now forecast in February.
Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the lowered forecast to emerging festival from compounded weight reduction medicine within the U.S.
“In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments,” Jørgensen stated in a observation.
“However, we have reduced our full-year outlook due to lowerthan-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the U.S.”
U.S. compounding pharmacies have been accredited to make prison copies of Novo’s Wegovy and diabetes drug Ozempic below a drug scarcity ruling by means of the Food and Drug Administration (FDA).
The FDA in February declared that scarcity over, giving compounding pharmacies till May 22 to stop promoting copies of the drug. However, Jørgensen reiterated Wednesday that the corporate would pursue firms that proceed to unlawfully distribute such copycat medicine.
Competition heats up
The effects come amid runaway call for for the drug maker’s blockbuster GLP-1 weight reduction therapies, which paintings by means of mimicking a hormone referred to as glucagon-like peptide-1 to suppress urge for food.
However, the corporate has struggled to shake destructive sentiment following a sequence of disappointing trial effects for its next-generation weight problems drug candidate CagriSema.
Competition is heating up within the weight reduction drug marketplace, with pharma corporations together with Roche, AstraZeneca and AbbVie all lately growing attainable new applicants.
Novo’s key U.S. rival Eli Lilly on Thursday reported an expectation-beating 45% upward thrust in first-quarter gross sales, even though revenues for its standard weight-loss drug Zepbound got here in quite not up to anticipated on decrease drug pricing. The U.S. drugmaker additionally diminished its full-year benefit steering because of fees associated with a contemporary most cancers remedy deal, sending stocks decrease.
